| The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma ES Scott, GV Long, A Guminski, RJ Clifton-Bligh, AM Menzies, VH Tsang European journal of endocrinology 178 (2), 173-180, 2018 | 140 | 2018 |
| Thyroid immune-related adverse events following immune checkpoint inhibitor treatment CA Muir, RJ Clifton-Bligh, GV Long, RA Scolyer, SN Lo, MS Carlino, ... The Journal of Clinical Endocrinology & Metabolism 106 (9), e3704-e3713, 2021 | 118 | 2021 |
| Checkpoint inhibitor–associated autoimmune diabetes is distinct from type 1 diabetes VHM Tsang, RT McGrath, RJ Clifton-Bligh, RA Scolyer, V Jakrot, ... The Journal of Clinical Endocrinology & Metabolism 104 (11), 5499-5506, 2019 | 107 | 2019 |
| Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: a systematic review L Wu, CB Nahm, NB Jamieson, J Samra, R Clifton‐Bligh, A Mittal, ... Clinical endocrinology 92 (5), 396-406, 2020 | 75 | 2020 |
| Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy K Kozusko, VHM Tsang, W Bottomley, YH Cho, S Gandotra, M Mimmack, ... Diabetes 64 (1), 299-310, 2015 | 73 | 2015 |
| A proposed grading scheme for medullary thyroid carcinoma based on proliferative activity (Ki-67 and mitotic count) and coagulative necrosis TL Fuchs, AJ Nassour, A Glover, MS Sywak, SB Sidhu, LW Delbridge, ... The American journal of surgical pathology 44 (10), 1419-1428, 2020 | 59 | 2020 |
| Multikinase inhibitors in thyroid cancer: timing of targeted therapy ML Gild, VHM Tsang, RJ Clifton-Bligh, BG Robinson Nature Reviews Endocrinology 17 (4), 225-234, 2021 | 56 | 2021 |
| Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer CA Muir, AM Menzies, R Clifton-Bligh, VHM Tsang Thyroid 30 (10), 1458-1469, 2020 | 55 | 2020 |
| Ultrasound-guided tissue-core biopsy of thoracic lesions with Trucut and Surecut needles JA Pang, V Tsang, BL Hom, C Metreweli Chest 91 (6), 823-828, 1987 | 52 | 1987 |
| BRAFV600E Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer S Fraser, C Go, A Aniss, S Sidhu, L Delbridge, D Learoyd, R Clifton-Bligh, ... World journal of surgery 40, 1618-1624, 2016 | 47 | 2016 |
| Molecular markers guiding thyroid cancer management C Nylén, R Mechera, I Maréchal-Ross, V Tsang, A Chou, AJ Gill, ... Cancers 12 (8), 2164, 2020 | 46 | 2020 |
| Thyroid cancer in the age of COVID-19 VHM Tsang, M Gild, A Glover, R Clifton-Bligh, BG Robinson Endocrine-Related Cancer 27 (11), R407-R416, 2020 | 43 | 2020 |
| Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours VHM Tsang, T Dwight, DE Benn, GY Meyer-Rochow, AJ Gill, M Sywak, ... Endocrine-Related Cancer 21 (3), 415-426, 2014 | 43 | 2014 |
| Papillary thyroid microcarcinoma: Is active surveillance always enough? R Sutherland, V Tsang, RJ Clifton‐Bligh, ML Gild Clinical Endocrinology 95 (6), 811-817, 2021 | 34 | 2021 |
| Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis SMC De Sousa, N Sheriff, CH Tran, AM Menzies, VHM Tsang, GV Long, ... Pituitary 21, 274-282, 2018 | 34 | 2018 |
| Hypercalcemia in glucagon cell hyperplasia and neoplasia (Mahvash syndrome): a new association ML Gild, V Tsang, J Samra, RJ Clifton-Bligh, L Tacon, AJ Gill The Journal of Clinical Endocrinology & Metabolism 103 (9), 3119-3123, 2018 | 30 | 2018 |
| The safety of vandetanib for the treatment of thyroid cancer VHM Tsang, BG Robinson, DL Learoyd Expert Opinion on Drug Safety 15 (8), 1107-1113, 2016 | 30 | 2016 |
| Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside L Wu, VHM Tsang, SC Sasson, AM Menzies, MS Carlino, DA Brown, ... Frontiers in Endocrinology 12, 764138, 2021 | 29 | 2021 |
| Association of antithyroid antibodies in checkpoint inhibitor–associated thyroid immune–related adverse events CA Muir, CCG Wood, RJ Clifton-Bligh, GV Long, RA Scolyer, MS Carlino, ... The Journal of Clinical Endocrinology & Metabolism 107 (5), e1843-e1849, 2022 | 25 | 2022 |
| Structural and functional consequences of succinate dehydrogenase subunit B mutations E Kim, EM Rath, VHM Tsang, AP Duff, BG Robinson, WB Church, ... Endocrine-related cancer 22 (3), 387-397, 2015 | 25 | 2015 |
